Delays in treatment initiation and conclusion in women with stage IA to IIIB cervical cancer: A survival study in a hospital-based cohort from a developing country

To evaluate the effect of delays in stage IA to IIIB cervical cancer treatment initiation and conclusion on hospital-based survival among Brazilian women. A retrospective follow-up study was conducted in a stage IA to IIIB cervical cancer cohort treated from 2012 and 2014 and followed until December...

Full description

Saved in:
Bibliographic Details
Published in:Cancer epidemiology 2023-10, Vol.86, p.102450-102450, Article 102450
Main Authors: da Silva, Ilce Ferreira, da Silva, Ileia Ferreira, Saraceni, Valéria, Koifman, Rosalina Jorge
Format: Article
Language:English
Subjects:
Brazil
Cancer
Cancer therapies
Cervical cancer
Death
Delay
Delays in treatment
Developing countries
Epidemiology
Hospital-based cohort
Hospitals
Industrialized nations
LDCs
Mortality
Multivariate analysis
Radiation therapy
Regression analysis
Risk
Survival
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effect of delays in stage IA to IIIB cervical cancer treatment initiation and conclusion on hospital-based survival among Brazilian women. A retrospective follow-up study was conducted in a stage IA to IIIB cervical cancer cohort treated from 2012 and 2014 and followed until December 31, 2017 in Rio de Janeiro. Delay in treatment initiation definition was defined based on the Brazilian law of 60 days for treatment initiation after diagnosis. Delay in treatment conclusion was defined based on the literature and sample distributions:  200 days. The endpoint was death(from all causes or cervical cancer). Death causes and dates were obtained by a record linkage procedure between the hospital cancer registry and the Mortality Information System. Global 36-month survival and HRs were estimated by the KaplanMeier method and proportional Cox regression models, respectively. From 865 patients, 269(31.1%) died over the median follow-up time of 27 months. Delay on treatment initiation(>60-days) was 92.8%, while the delay in treatment conclusion(>120 days) was 87.5%. Overall survival was 61.3% (
ISSN:1877-7821
1877-783X
DOI:10.1016/j.canep.2023.102450